Alex Oh
Corporate Officer/Principal chez DYNAVAX TECHNOLOGIES CORPORATION
Profil
Alex Oh is currently the Vice President-Intellectual Property at Dynavax Technologies Corp.
Prior to this, Mr. Oh held positions as a Partner at Technology & Intellectual Property Group and Stoel Rives LLP.
Mr. Oh also served as Senior Counsel at Juno Therapeutics, Inc. and Vice President-Legal & IP at Visus Therapeutics, Inc. Mr. Oh's education includes an undergraduate degree from the University of Washington, a graduate degree from the University of Wisconsin, and an undergraduate degree from the University of Wisconsin Law School.
Postes actifs de Alex Oh
| Sociétés | Poste | Début |
|---|---|---|
| DYNAVAX TECHNOLOGIES CORPORATION | Corporate Officer/Principal | 01/01/2022 |
Anciens postes connus de Alex Oh
| Sociétés | Poste | Fin |
|---|---|---|
Stoel Rives LLP
 Stoel Rives LLP Miscellaneous Commercial ServicesCommercial Services Stoel Rives LLP provides full suite of transactional and litigation solutions for U.S. and international clients. Its practice areas include corporate, energy, environmental, intellectual property, labor and employment, land use and construction, litigation, natural resources, real estate, renewable energy and technology law. The firm?s clients include financial institutions, public and private utilities, energy and renewable energy companies, developers, manufacturers, retailers, hospitals, universities, agribusinesses, software companies, food and beverage companies, charitable foundations, telecommunications and forestry companies, among others. The company was founded in 1907 and is headquartered in Portland, OR. | Corporate Officer/Principal | - |
| JUNO THERAPEUTICS INC | General Counsel | - |
| Technology & Intellectual Property Group | Corporate Officer/Principal | - |
Visus Therapeutics, Inc.
 Visus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation. | General Counsel | - |
Formation de Alex Oh
| University of Washington | Undergraduate Degree |
| University of Wisconsin | Graduate Degree |
| University of Wisconsin Law School | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| DYNAVAX TECHNOLOGIES CORPORATION | Health Technology |
| Entreprise privées | 4 |
|---|---|
Stoel Rives LLP
Stoel Rives LLP Miscellaneous Commercial ServicesCommercial Services Stoel Rives LLP provides full suite of transactional and litigation solutions for U.S. and international clients. Its practice areas include corporate, energy, environmental, intellectual property, labor and employment, land use and construction, litigation, natural resources, real estate, renewable energy and technology law. The firm?s clients include financial institutions, public and private utilities, energy and renewable energy companies, developers, manufacturers, retailers, hospitals, universities, agribusinesses, software companies, food and beverage companies, charitable foundations, telecommunications and forestry companies, among others. The company was founded in 1907 and is headquartered in Portland, OR. | Commercial Services |
| Technology & Intellectual Property Group | |
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
Visus Therapeutics, Inc.
Visus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation. | Health Technology |
